Treatment guidelines recommend that everyone with HIV starts treatment whatever their CD4 count. Effective treatment protects your immune system and ensures that if your viral load is undetectable, you cannot pass on HIV.
Eventually, nearly everyone with HIV will become ill without treatment.
If you're not on effective HIV treatment, the virus can attack and weaken your immune system (the body’s natural defence against infections).
Over time, when HIV has done a lot of damage to your immune system, you're likely to become vulnerable to infections that you would otherwise have been able to fight off.
HIV also causes inflammation in various parts of the body. This can increase the risk of a number of illnesses: cardiovascular disease (for example, heart attack and stroke), kidney or liver problems and some cancers.
The damage that HIV causes happens slowly, often over a number of years. It can be the case that a person feels well during this time.
Treatment protects you. A person with HIV who is taking treatment and has an undetectable viral load cannot pass on HIV and can expect to live a normal lifespan.
It can take up to six months on treatment to become undetectable.
You should start taking HIV treatment as soon as you're diagnosed.
Until recently, people living with HIV were advised to start treatment before their CD4 count dropped to 350 or below.
The British HIV Association (BHIVA) now recommends that anyone with HIV who is ready to commit to treatment should start taking it regardless of CD4 count.
Those changes reflect the findings of the START study. It found that people who delayed treatment until their CD4 count dropped to 350 had a significantly higher chance of developing AIDS-related illnesses such as cancers.
In the past people could delay treatment if they weren’t ready to start. However, this isn’t recommended now.
The START trial found that there was a 53% reduction in the risk of death or serious illness if treatment was started when the CD4 count was still above 500.
It’s common for people to feel apprehensive about taking treatment but all you need to remember is that:
If you're nervous a healthcare professional at your clinic will be able to reassure you. They'll be able to explore with you the reasons why you don't want to start. You can also contact THT Direct on 0808 802 1221 for support around your decision.
Next: Dealing with side-effects of HIV treatment ››
‹‹ Back to: About HIV treatment
See also: Full HIV medication listings ›››
(1 vote cast)
Please log in
or register to vote.
to add this article to My favourites.
Adding an article to My favourites will allow you to easily come back to it later or print it.
This article was last reviewed on
by Anna Peters
Date due for the next review: 1/11/2018
Content Author: Kerri Virani
Current Owner: Kerri Virani
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy, Mujugira A1, Celum C, Coombs RW, Campbell JD, Ndase P, Ronald A, Were E, Bukusi EA, Mugo N, Kiarie J, Baeten JM; Partners PrEP Study Team
National Center for Biotechnology Information
US National Library of Medicine
2016 Aug 15;72(5):579-84. doi: 10.1097/QAI.0000000000001019
HIV treatment as prevention and HPTN 052, Cohen MS1, McCauley M, Gamble TR
National Center for Boiotechnology Information
US National Library of Medicine
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy, Journal of the American Medical Association: Alison J. Rodger, MD; Valentina Cambiano, PhD; Tina Bruun, RN; Pietro Vernazza, MD; Simon Collins; Jan van Lunzen, PhD; Giulio Maria Corbelli; Vicente Estrada, MD; Anna Maria Geretti, MD; Apostolos Beloukas, PhD; David Asboe, FRCP; Pompeyo Viciana, MD1; Félix Gutiérrez, MD; Bonaventura Clotet, PhD; Christian Pradier, MD; Jan Gerstoft, MD; Rainer Weber, MD; Katarina Westling, MD; Gilles Wandeler, MD; Jan M. Prins, PhD; Armin Rieger, MD; Marcel Stoeckle, MD; Tim Kümmerle, PhD; Teresa Bini, MD; Adriana Ammassari, MD; Richard Gilson, MD; Ivanka Krznaric, PhD; Matti Ristola, PhD; Robert Zangerle, MD; Pia Handberg, RN; Antonio Antela, PhD; Sris Allan, FRCP; Andrew N. Phillips, PhD; Jens Lundgren, MD, JAMA. 2016;316(2):171-181. doi:10.1001/jama.2016.5148
Viral load, Michael Carter, Greta Hughson, NAM, Aidsmap, March 2014
More confidence on zero risk: still no transmissions seen from people with an undetectable viral load in PARTNER study, Gus Cairns, NAM, Aidsmap, July 2016
BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015, Writing Group:
Duncan Churchill Chair Laura Waters Vice Chair N Ahmed, B Angus, M Boffito, M Bower, D Dunn, S Edwards, C Emerson, S Fidler, †M Fisher, R Horne, S Khoo, C Leen, N Mackie, N Marshall, F Monteiro, M Nelson, C Orkin, A Palfreeman, S Pett, A Phillips, F Post, A Pozniak, I Reeves, C Sabin, R Trevelion, J Walsh, E Wilkins, I Williams, A Winston
New British guidelines recommend treatment for everyone living with HIV
NAM, Aidsmap, Keith Alcorn, 24/6/15
No one with an undetectable viral load, gay or heterosexual, transmits HIV in first two years of PARTNER study, NAM, Aidsmap, Gus Cairns, 4/3/14
START trial finds that early treatment improves outcomes for people with HIV, NAM, Aidsmap, Gus Cairns, 27/5/15
START trial provides definitive evidence of the benefits of early HIV treatment, NAM, Aidsmap, Liz Highleyman, Produced in collaboration with hivandhepatitis.com, 21/7/15
Various people talk about their experiences of living with HIV.
CAB - Citizens Advice Bureau
HIV Drug Interactions
George House Trust
Equality and Human Rights Commission
Copyright 2017 © Terrence Higgins Trust is a registered charity in England and Wales (reg. no. 288527)
Company reg. no. 1778149 and a registered charity in Scotland (reg. no. SC039986). Registered office: 314-320 Gray's Inn Road, London, WC1X 8DP.